Association of changes in the type 2 diabetes and MASLD /related SLD status with risk of developing cardiovascular disease
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yasuhiro Matsubayashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background & Aims This study assessed the association of remission of type 2 diabetes mellitus (DM) or metabolic dysfunction‐associated steatotic liver disease (MASLD)/related SLD (r‐SLD; MASLD with excessive alcohol intake) as defined by the fatty liver index with the risk of cardiovascular disease (CVD).
Methods
Health examination data at baseline and after 2 years (2‐Years) were extracted from a nationwide claims database in Japan. Among participants aged 18–72 years with at least 3 years of follow‐up, 9345 participants with DM‐associated MASLD/r‐SLD and 71 932 participants with non‐DM MASLD/r‐SLD at baseline were included in the study. The participants were stratified by the achievement of remission of MASLD/r‐SLD or DM at 2‐Years. In each group after stratification, the risk of new‐onset CVD during the observation period was analysed using multivariate Cox proportional hazards models.
Results
During a median follow‐up of 4.9 years (starting from 2‐Years), 1368 cases of CVD were observed. The hazard ratio (95% confidence interval) for CVD was 0.50 (0.31–0.80) for participants with remission of DM, 0.65 (0.47–0.91) for participants with remission of MASLD/r‐SLD, and 0.34 (0.15–0.77) for participants with remission of both DM and MASLD/r‐SLD. Conversely, remission of MASLD/r‐SLD was not linked to a reduced risk of CVD in participants with non‐DM MASLD/r‐SLD.
Conclusion
The association of MASLD/r‐SLD remission with CVD risk differs greatly in the presence and absence of DM. In patients with DM‐MASLD/r‐SLD, MASLD/r‐SLD remission can significantly reduce CVD risk similarly as remission of DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
ORCID-Profile: Yasuhiro Matsubayashi, Kazuya Fujihara, Laymon Khin, Satoru Kodama
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Matsubayashi, Y., Fujihara, K., Khin, L., Ferreira, E. D., Takabayashi, S., Yamashita, Y., Yamada, T., Kodama, S., & Sone, H. (2025). Association of changes in the type 2 diabetes and MASLD /related SLD status with risk of developing cardiovascular disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16196
Vancouver
Matsubayashi Y, Fujihara K, Khin L, Ferreira ED, Takabayashi S, Yamashita Y, et al. Association of changes in the type 2 diabetes and MASLD /related SLD status with risk of developing cardiovascular disease. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16196
BibTeX
@article{Matsubayashi2025,
author = {Matsubayashi, Yasuhiro and Fujihara, Kazuya and Khin, Laymon and Ferreira, Efrem d'Àvila and Takabayashi, Shizuka and Yamashita, Yuko and Yamada, Takaho and Kodama, Satoru and Sone, Hirohito},
title = {Association of changes in the type 2 diabetes and MASLD /related SLD status with risk of developing cardiovascular disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16196}
}
EUVIMED